S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:VYNE

VYNE Therapeutics (VYNE) Stock Price, News & Analysis

$3.07
+0.11 (+3.72%)
(As of 03/28/2024 ET)
Today's Range
$2.86
$3.09
50-Day Range
$1.71
$3.07
52-Week Range
$1.67
$8.73
Volume
294,678 shs
Average Volume
137,814 shs
Market Capitalization
$43.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.38

VYNE Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
140.2% Upside
$7.38 Price Target
Short Interest
Healthy
0.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.05mentions of VYNE Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.00) to ($0.96) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.82 out of 5 stars

Medical Sector

260th out of 938 stocks

Pharmaceutical Preparations Industry

112th out of 417 stocks

VYNE stock logo

About VYNE Therapeutics Stock (NASDAQ:VYNE)

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE Stock Price History

VYNE Stock News Headlines

VYNE Therapeutics (NASDAQ:VYNE) Stock Price Up 3.9%
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Recap: VYNE Therapeutics Q3 Earnings
See More Headlines
Receive VYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VYNE
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.38
High Stock Price Target
$9.00
Low Stock Price Target
$5.75
Potential Upside/Downside
+140.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-28,450,000.00
Net Margins
-6,710.38%
Pretax Margin
-6,573.58%

Debt

Sales & Book Value

Annual Sales
$420,000.00
Book Value
$6.36 per share

Miscellaneous

Free Float
13,845,000
Market Cap
$43.29 million
Optionable
Not Optionable
Beta
1.18
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. David T. Domzalski (Age 57)
    CEO, President & Director
    Comp: $1.61M
  • Dr. Iain A. Stuart Ph.D. (Age 51)
    Chief Scientific Officer
    Comp: $856.82k
  • Ms. Mutya Harsch J.D. (Age 49)
    General Counsel, Chief Legal Officer & Company Secretary
    Comp: $817.97k
  • Mr. Tyler Zeronda (Age 37)
    CFO & Treasurer
  • Dr. Darrell S. Rigel Faad (Age 73)
    M.D., Ms, Consultant
    Comp: $40.2k

VYNE Stock Analysis - Frequently Asked Questions

Should I buy or sell VYNE Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VYNE shares.
View VYNE analyst ratings
or view top-rated stocks.

What is VYNE Therapeutics' stock price target for 2024?

1 brokers have issued 1 year price targets for VYNE Therapeutics' shares. Their VYNE share price targets range from $5.75 to $9.00. On average, they anticipate the company's share price to reach $7.38 in the next twelve months. This suggests a possible upside of 140.2% from the stock's current price.
View analysts price targets for VYNE
or view top-rated stocks among Wall Street analysts.

How have VYNE shares performed in 2024?

VYNE Therapeutics' stock was trading at $2.33 at the beginning of 2024. Since then, VYNE stock has increased by 31.8% and is now trading at $3.07.
View the best growth stocks for 2024 here
.

Are investors shorting VYNE Therapeutics?

VYNE Therapeutics saw a drop in short interest in March. As of March 15th, there was short interest totaling 12,400 shares, a drop of 63.4% from the February 29th total of 33,900 shares. Based on an average daily trading volume, of 117,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the shares of the company are short sold.
View VYNE Therapeutics' Short Interest
.

When is VYNE Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VYNE earnings forecast
.

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) issued its quarterly earnings results on Thursday, February, 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.30. The company had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.15 million. VYNE Therapeutics had a negative trailing twelve-month return on equity of 77.46% and a negative net margin of 6,710.38%.

When did VYNE Therapeutics' stock split?

VYNE Therapeutics shares reverse split on the morning of Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Organigram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).

Who are VYNE Therapeutics' major shareholders?

VYNE Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (9.99%), Citadel Advisors LLC (8.46%), Parkman Healthcare Partners LLC (4.99%), Palo Alto Investors LP (3.19%), Prelude Capital Management LLC (0.85%) and Exome Asset Management LLC (0.85%). Insiders that own company stock include Mutya Harsch, Patrick G Lepore and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of VYNE Therapeutics?

Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VYNE) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners